Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Gynaecological Cancer Update for GPs R D Clayton MD MRCOG Consultant Gynae Oncologist Gynaecological Cancer Incidence 2011 Gynaecological Cancer mortality 2010 Urgent Gynaecological Cancer Referral NICE Guidelines Refer Urgently: with clinical features suggestive of cervical cancer on examination. A smear test is not required before referral, and a previous negative result should not delay referral not on hormone replacement therapy with postmenopausal bleeding on hormone replacement therapy with persistent or unexplained postmenopausal bleeding after cessation of hormone replacement therapy for 6 weeks taking tamoxifen with postmenopausal bleeding Urgent Gynaecological Cancer Referral Refer Urgently: with an unexplained vulval lump or with vulval bleeding due to ulceration Consider urgent referral for patients with persistent intermenstrual bleeding and negative pelvic examination Refer urgently for an ultrasound scan patients: with a palpable abdominal or pelvic mass on examination that is not obviously uterine fibroids or not of gastrointestinal or urological origin. If the scan is suggestive of cancer, an urgent referral should be made. If urgent ultrasound is not available, an urgent referral should be made Ovary - Case History 1 65 yo woman presents with 3 month history of abdominal bloating, and pelvic pain, with symptoms suggestive of IBS. Prior to this she had been well. Q1. What are the most important investigations Ovary - Case History 1 Q1. What are the most important investigations? • • • • Ultrasound scan abdo/pelvis CA125 measurement Clinical examination Bowel investigations Ovarian Cancer: the recognition and initial management of ovarian cancer Full guideline April 2011 Developed for NICE by the National Collaborating Centre for Cancer Ovarian Cancer: Nice Guidelines • Focuses on areas of uncertainty • GPs are often criticised for delays in diagnosis • Relatively rare cancer (5th commonest) • Symptoms often none specific Ovarian Cancer: Nice Guidelines ‘tests’ should be carried out in primary care if a woman (especially if 50 or over) reports having any of the following symptoms on a persistent or frequent basis; • persistent abdominal distension • feeling full (early satiety) and/or loss of appetite • pelvic or abdominal pain. • increased urinary urgency and/or frequency. Ovarian Cancer: Nice Guidelines • Consider carrying out ‘tests’ in primary care if a woman reports unexplained weight loss, fatigue or changes in bowel habit. • Advise any woman who is not suspected of having ovarian cancer to return to her GP if her symptoms become more frequent and/or persistent. • Carry out appropriate tests for ovarian cancer in any woman of 50 or over who has experienced symptoms within the last 12 months that suggest irritable bowel syndrome (IBS), because IBS rarely presents for the first time in women of this age. Ovarian Cancer: Nice Guidelines BUT WHAT TEST SHOULD WE DO? Ovarian Cancer: Nice Guidelines • Clinical evidence and Health economic evaluation was performed. • Initial test should be CA125 • If this is raised then perform an ultrasound • If both are ‘positive’ refer to secondary care (Sequential testing) Ovarian Cancer Management What can you tell the patient? • • • • Laparotomy – what this entails Risks and additional procedures Any Chemotherapy pre op or post op? Types of chemotherapy Case History 2 The previous patient comes to the surgery with her 45 year old daughter who has had 3 episodes of abdominal bloating in the last month related to food but no change in bowel habit. Q2. Would you measure her CA125 level? Case History 2 CA125 levels – pitfalls • Not elevated in up to 50% of stage 1 ovarian cancers • Can be raised for other reasons • Benign ovarian cysts eg endometriosis • Fibroids • Connective tissue disorders • Heart failure/liver failure • Other malignancies eg breast or lung Case History 2 Consequences? • Unnecessary investigations • Unnecessary interventions Ovarian cancer OVARIAN CANCER Key Developments When should we operate? How much ‘surgical effort’ should we make? Original Article Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer Ignace Vergote, M.D., Ph.D., Claes G. Tropé, M.D., Ph.D., Frédéric Amant, M.D., Ph.D., Gunnar B. Kristensen, M.D., Ph.D., Tom Ehlen, M.D., Nick Johnson, M.D., René H.M. Verheijen, M.D., Ph.D., Maria E.L. van der Burg, M.D., Ph.D., Angel J. Lacave, M.D., Pierluigi Benedetti Panici, M.D., Ph.D., Gemma G. Kenter, M.D., Ph.D., Antonio Casado, M.D., Cesar Mendiola, M.D., Ph.D., Corneel Coens, M.Sc., Leen Verleye, M.D., Gavin C.E. Stuart, M.D., Sergio Pecorelli, M.D., Ph.D., Nick S. Reed, M.D., for the European Organization for Research and Treatment of Cancer– Gynaecological Cancer Group and the NCIC Clinical Trials Group — a Gynecologic Cancer Intergroup Collaboration N Engl J Med Volume 363(10):943-953 September 2, 2010 EORTC Study Overview • Randomized trial, standard primary debulking surgery followed by chemotherapy was compared with neoadjuvant chemotherapy followed by debulking surgery in women with bulky stage IIIC or IV ovarian cancer. • Starting treatment with chemotherapy allowed more patients to undergo optimal tumor debulking during the subsequent operation. • However, the outcomes were the same regardless of the timing of the debulking operation. • Primary chemotherapy is an option in the management of bulky ovarian cancer. EORTC Study Overview • Surgical Effort – how far should we go? • Is Chemotherapy the important factor? • Is ability to debulk related to the inherent tumour biology. • Is perioperative morbidity greater with upfront debulking surgery. OVARIAN CANCER Key Developments OV05 study 2010 Do not retreat on the basis of a raised CA125 level OVARIAN CANCER Key Developments •Bevacizumab (VEGF inhibitor) in addition to carbotaxol •Role of intraperitoneal chemotherapy – being tested in PETROC trial 20.0 all uterus body of uterus uterus unspecified 15.0 10.0 5.0 Year of diagnosis 2007 2005 2003 2001 1999 1997 1995 1993 1991 1989 1987 1985 1983 1981 1979 1977 0.0 1975 Rate per 100,000 population Figure 1.5: Age-standardised (European) incidence rates, uterus cancer, by sex, GB, 1975-2007 Endometrial Cancer Case History? A 70 year old woman presents with 3 episodes of heavy post menopausal bleeding. Q1 What are the referral options? Q2 What investigations will be performed? Endometrial Adenocarcinoma Pre-operative Imaging •TV USS useful as diagnostic/screening tool •One stop PMB clinic is the gold standard •MRI is the method of choice for radiological staging once diagnosis established •Best for prediction of depth of myometrial invasion and cervix involvement Endometrial Adenocarcinoma Management • Consider laparoscopic approach • Role of lymph node removal uncertain (ASTEC) • Role of brachytherapy – (PORTEC 2) 18 16 females 14 12 10 8 6 4 2 Year of diagnosis 2005 2002 1999 1996 1993 1990 1987 1984 1981 1978 0 1975 Rate per 100,000 population Figure 1.2: Age standardised (European) incidence rates, cervical cancer, Great Britain, 1975-2007 Cervix Cancer Aetiology • Pre-invasive phase of CIN • Usually due to HPV Aetiology Management of High grade CIN Management of High grade CIN What are the risks of loop excision? Management of CIN Cervix case history 1 A 35 year old woman consults you as she is very worried about the possibility of cervix cancer and wants to be vaccinated. She has had a loop excision for CIN 3 approx 5 years before with negative smears since Q. What would you advise her? Cervix case history 2 She wants to know how long the vaccine will work for and whether she will need any booster injections at a later date? Q. What would you advise her? Cervix case history 3 The same woman brings along her son who is aged 13 saying that she has heard it is a good idea to have him vaccinated against HPV Q. What would you advise her? HPV vaccination • Cervarix for national programme changed to Gardasil • Will routine smears be necessary in the future? • HPV vaccination for older women? • Duration of immunity? • HPV vaccination for males? HPV vaccination • Cervarix for national programme • HPV triage and test of cure HPV triage and test of cure Cervix – Case History 4 A 22 yr old nulliparous woman presents with an abnormal appearing cervix. You are concerned there may be a cervical cancer and the patient asks you what options may be available for treatment. Q – What would you tell her? Cervix – Case History •Radical Hysterectomy •Radical Trachelectomy •ChemoRadiotherapy Management Stage IB or IIA disease No difference between • Radical Hysterectomy or • Radiotherapy (Landoni et al, Lancet, 1997) Fertility sparing surgery for stage IB or IA2 • Radical Trachelectomy and laparoscopic lymphadenectomy Conclusions Recent major changes in management of • Ovarian • Endometrial • Cervical ANY QUESTIONS Any questions? www.northwestgynaecology.co.uk At the Alexandra Hospital Gail Busby: Paed Gynae Rick Clayton: Gynae Onc Edi Edi-Osagie: Fertility Kristina Naidoo: Hysteroscopy Rick Clayton 07796267881 Group Secretary 01612482026 (Lesley) [email protected] Tony Smith: Urogynae/prolapse